Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
about
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@en
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@nl
type
label
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@en
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@nl
prefLabel
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@en
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@nl
P2093
P2860
P921
P1476
Open-label phase 1b study of F ...... dvanced or metastatic disease.
@en
P2093
Emily Chan
Eunice L Kwak
Guillaume de La Bourdonnaye
Jimmy Hwang
Marja Heiskala
Monica Mita
P2860
P2888
P304
P356
10.1007/S00280-015-2682-2
P577
2015-01-28T00:00:00Z